Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 10/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249083 | 0.89 | CYP11B1 (0.44) | CYP11B1CYP11B2PDE2APDE10ACYP1A2 | |
| SCHEMBL13063638 | 0.74 | PIK3CA (0.51) | PDE10APIK3CAMAPK14GRM5 | |
| SCHEMBL2125696 | 0.74 | PIK3CA (0.44) | CYP11B1CYP11B2CYP3A4PIK3CACYP17A1 | |
| SCHEMBL2125276 | 0.73 | PIK3CA (0.45) | CYP11B1CYP11B2PIK3CA | |
| SCHEMBL2711406 | 0.73 | PIK3CA (0.38) | CYP11B1CYP11B2PDE2APIK3CA | |
| SCHEMBL17896703 | 0.72 | CYP11B1 (0.50) | CYP11B1CYP11B2PDE2APDE10ACYP1A2 | |
| SCHEMBL12992181 | 0.69 | PIK3CA (0.40) | PDE10APIK3CA | |
| SCHEMBL2124466 | 0.69 | CYP11B1 (0.38) | CYP11B1CYP11B2PIK3CA | |
| SCHEMBL13063909 | 0.68 | APP (0.40) | — | |
| SCHEMBL2126073 | 0.68 | PIK3CA (0.49) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | CYP11B1 1418/4885CYP11B2 1364/4885PDE2A 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.